Progress Toward Cardiac Risk Reduction With the Evolution of Pediatric Hodgkin Lymphoma Therapy
Author:
Affiliation:
1. Division of Pediatric Hematology/Oncology, Seattle Children’s Hospital, University of Washington, Seattle
2. Department of Pediatrics, University of California, San Diego
3. Rady Children’s Hospital San Diego, San Diego, California
Publisher
American Medical Association (AMA)
Link
https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2814096/leger_2024_ic_230209_1704921096.16414.pdf
Reference8 articles.
1. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials.;Kahn;Lancet Haematol,2022
2. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.;Armstrong;J Clin Oncol,2013
3. Late cardiac toxic effects associated with treatment protocols for Hodgkin lymphoma in children.;Lo;JAMA Netw Open,2024
4. Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: a report from the Childhood Cancer Survivor Study.;Oeffinger;J Clin Oncol,2021
5. T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma.;Moskowitz;Hemasphere,2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3